128.54
price up icon0.71%   0.91
 
loading
Abbott Laboratories stock is traded at $128.54, with a volume of 6.80M. It is up +0.71% in the last 24 hours and down -4.20% over the past month. Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$127.63
Open:
$127.86
24h Volume:
6.80M
Relative Volume:
1.07
Market Cap:
$223.72B
Revenue:
$43.84B
Net Income/Loss:
$13.94B
P/E Ratio:
16.07
EPS:
7.9979
Net Cash Flow:
$6.78B
1W Performance:
-3.04%
1M Performance:
-4.20%
6M Performance:
-1.86%
1Y Performance:
+9.03%
1-Day Range:
Value
$127.21
$129.26
1-Week Range:
Value
$125.74
$133.34
52-Week Range:
Value
$110.86
$140.84

Abbott Laboratories Stock (ABT) Company Profile

Name
Name
Abbott Laboratories
Name
Phone
(224) 667-6100
Name
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Name
Employee
114,000
Name
Twitter
@AbbottNews
Name
Next Earnings Date
2025-10-15
Name
Latest SEC Filings
Name
ABT's Discussions on Twitter

Compare ABT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Devices icon
ABT
Abbott Laboratories
128.54 222.13B 43.84B 13.94B 6.78B 7.9979
Medical Devices icon
BSX
Boston Scientific Corp
99.24 144.89B 18.49B 2.50B 3.49B 1.6801
Medical Devices icon
SYK
Stryker Corp
374.42 141.17B 23.82B 2.92B 4.02B 7.5574
Medical Devices icon
MDT
Medtronic Plc
95.78 121.91B 34.20B 4.69B 5.30B 3.6218
Medical Devices icon
EW
Edwards Lifesciences Corp
74.64 42.65B 5.69B 1.41B 577.90M 6.9828

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-10-25 Initiated The Benchmark Company Buy
Jul-18-25 Upgrade Jefferies Hold → Buy
Jun-16-25 Initiated Leerink Partners Market Perform
Oct-08-24 Initiated Oppenheimer Outperform
Sep-19-24 Initiated Piper Sandler Overweight
Jul-30-24 Downgrade Edward Jones Buy → Hold
May-30-24 Initiated Goldman Buy
Jul-21-23 Upgrade Wolfe Research Underperform → Peer Perform
May-30-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-20-23 Reiterated Barclays Overweight
Apr-20-23 Reiterated Bernstein Outperform
Apr-20-23 Reiterated JP Morgan Overweight
Apr-20-23 Reiterated Raymond James Outperform
Apr-20-23 Reiterated UBS Buy
Apr-20-23 Reiterated Wolfe Research Underperform
Mar-29-23 Initiated UBS Buy
Oct-26-22 Initiated Mizuho Neutral
Oct-18-22 Initiated Barclays Overweight
Oct-12-22 Initiated Jefferies Hold
Jul-06-22 Initiated Wolfe Research Underperform
Mar-02-22 Resumed BofA Securities Buy
Jan-27-22 Reiterated Credit Suisse Outperform
Jan-27-22 Reiterated Morgan Stanley Overweight
Jan-27-22 Reiterated Raymond James Outperform
Jan-27-22 Reiterated UBS Buy
Dec-10-21 Initiated RBC Capital Mkts Outperform
Oct-27-21 Upgrade Atlantic Equities Neutral → Overweight
Oct-14-21 Initiated Redburn Neutral
May-25-21 Initiated Barclays Overweight
Apr-15-21 Initiated Atlantic Equities Neutral
Jan-28-21 Upgrade BTIG Research Neutral → Buy
Sep-11-20 Initiated Wolfe Research Outperform
Jun-01-20 Downgrade Goldman Neutral → Sell
Mar-05-20 Initiated Citigroup Buy
Feb-13-20 Initiated Goldman Neutral
Feb-06-20 Resumed BTIG Research Neutral
Jan-02-20 Downgrade Guggenheim Buy → Neutral
Jun-13-19 Reiterated BofA/Merrill Buy
Feb-07-19 Reiterated BofA/Merrill Buy
Jan-02-19 Downgrade Citigroup Neutral → Sell
Nov-30-18 Upgrade Goldman Neutral → Buy
Oct-16-18 Initiated Barclays Overweight
Jun-27-18 Initiated Bernstein Outperform
Jan-30-18 Reiterated Citigroup Neutral
Jan-25-18 Reiterated Stifel Buy
Jan-25-18 Upgrade William Blair Mkt Perform → Outperform
Jan-03-18 Initiated Evercore ISI Outperform
Jan-02-18 Upgrade JP Morgan Neutral → Overweight
Jan-02-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-19-17 Reiterated RBC Capital Mkts Outperform
Oct-19-17 Reiterated Stifel Buy
View All

Abbott Laboratories Stock (ABT) Latest News

pulisher
Oct 18, 2025

How Abbott Laboratories stock reacts to job market data2025 Market Outlook & Verified High Yield Trade Plans - Trung tâm Dự báo KTTV quốc gia

Oct 18, 2025
pulisher
Oct 18, 2025

What makes Abbott Laboratories stock attractive to growth fundsPortfolio Profit Report & Safe Entry Momentum Tips - Trung tâm Dự báo KTTV quốc gia

Oct 18, 2025
pulisher
Oct 18, 2025

Abbott: GLP-1 BeneficiaryDividend Raise May Be Coming (NYSE:ABT) - Seeking Alpha

Oct 18, 2025
pulisher
Oct 18, 2025

How Abbott Laboratories stock compares to growth peersMarket Trend Review & Weekly High Return Stock Opportunities - Trung tâm Dự báo KTTV quốc gia

Oct 18, 2025
pulisher
Oct 18, 2025

Is Abbott Laboratories (ABL) stock cheap by valuation metricsForecast Cut & Free Reliable Trade Execution Plans - Trung tâm Dự báo KTTV quốc gia

Oct 18, 2025
pulisher
Oct 17, 2025

How Abbott Laboratories stock responds to policy changes2025 Earnings Impact & AI Based Buy/Sell Signal Reports - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Is Abbott Laboratories stock a good choice for value investors2025 Market Overview & Community Trade Idea Sharing - nchmf.gov.vn

Oct 17, 2025
pulisher
Oct 17, 2025

Q&A: What cardiologists know and don’t know about pulsed field ablation - Cardiovascular Business

Oct 17, 2025
pulisher
Oct 17, 2025

Abbott Laboratories' October Price Plunge Is a Signal to Buy - MSN

Oct 17, 2025
pulisher
Oct 17, 2025

Abbott Labs stock price target raised to $158 from $154 at UBS - Investing.com

Oct 17, 2025
pulisher
Oct 17, 2025

Abbott Laboratories' October Price Plunge Is A Signal To Buy - Barchart.com

Oct 17, 2025
pulisher
Oct 17, 2025

Abbott Laboratories Stock (ABT) Opinions on Q3 2025 Earnings Report - Quiver Quantitative

Oct 17, 2025
pulisher
Oct 17, 2025

Can Abbott (ABT) Balance Medical Devices Growth Against Diagnostics Challenges in 2025? - simplywall.st

Oct 17, 2025
pulisher
Oct 17, 2025

Abbott Laboratories price pressured by negative technical patternForecast today17-10-2025 - Economies.com

Oct 17, 2025
pulisher
Oct 17, 2025

Abbott Laboratories (ABT) Stock forecasts - Yahoo

Oct 17, 2025
pulisher
Oct 17, 2025

Is Abbott Laboratories stock a buy in volatile marketsSwing Trade & Free Weekly Watchlist of Top Performers - newser.com

Oct 17, 2025
pulisher
Oct 17, 2025

Abbott Eyes Strong US Diabetes Growth In 2026, Diagnostics Recovery As China Headwinds Ease - insights.citeline.com

Oct 17, 2025
pulisher
Oct 16, 2025

Analyst See Noise In Q3 P&L, Affirms Abbott's Medtech Strength - Benzinga

Oct 16, 2025
pulisher
Oct 16, 2025

These Analysts Revise Their Forecasts On Abbott Following Q3 Results - Benzinga

Oct 16, 2025
pulisher
Oct 16, 2025

Abbott Laboratories Keeps Its Cool Despite A Slight Sales Miss - Finimize

Oct 16, 2025
pulisher
Oct 16, 2025

Abbott Laboratories Q3 2025 Earnings: Stable Growth Amid Tariff And China Headwinds - Seeking Alpha

Oct 16, 2025
pulisher
Oct 16, 2025

Abbott cuts top end of 2025 guidance as tariff threat looms - Modern Healthcare

Oct 16, 2025
pulisher
Oct 16, 2025

UBS reiterates Buy rating on Abbott Labs stock amid sustainable MedTech growth - Investing.com India

Oct 16, 2025
pulisher
Oct 16, 2025

Barclays Adjusts Abbott Laboratories Price Target to $162 From $159 - MarketScreener

Oct 16, 2025
pulisher
Oct 16, 2025

Abbott Labs Q3 2025: Medical Devices Drive 6.9% Sales Growth - Dallas Express

Oct 16, 2025
pulisher
Oct 16, 2025

Abbott Labs stock rating reiterated at Buy by Benchmark on strong device sales - Investing.com

Oct 16, 2025
pulisher
Oct 16, 2025

A Quick Look at Today's Ratings for Abbott Laboratories(ABT.US), With a Forecast Between $142 to $150 - 富途牛牛

Oct 16, 2025
pulisher
Oct 16, 2025

Abbott Laboratories (NYSE:ABT) Q3 2025 Earnings Call Transcript - MSN

Oct 16, 2025
pulisher
Oct 16, 2025

Jefferies Adjusts Price Target on Abbott Laboratories to $149 From $145, Maintains Buy Rating - MarketScreener

Oct 16, 2025
pulisher
Oct 16, 2025

Bernstein Adjusts Abbott Laboratories Price Target to $150 From $145, Maintains Outperform Rating - MarketScreener

Oct 16, 2025
pulisher
Oct 16, 2025

Raymond James Adjusts Abbott Laboratories Price Target to $146 From $141, Maintains Outperform Rating - MarketScreener

Oct 16, 2025
pulisher
Oct 16, 2025

Jefferies Adjusts Abbott Laboratories Price Target to $149 From $145, Maintains Buy Rating - MarketScreener

Oct 16, 2025
pulisher
Oct 16, 2025

Abbott Labs stock rating reiterated at Outperform by RBC despite mixed results - Investing.com India

Oct 16, 2025
pulisher
Oct 16, 2025

Abbott’s strong Q3 medtech performance offset by diagnostic weakness - Medical Device Network

Oct 16, 2025
pulisher
Oct 16, 2025

Abbott Labs stock price target raised to $146 by Wells Fargo on Medtech strength - Investing.com India

Oct 16, 2025
pulisher
Oct 16, 2025

Jefferies raises Abbott Labs stock price target to $146 on medical device growth - Investing.com

Oct 16, 2025
pulisher
Oct 16, 2025

Abbott Laboratories: Strong Growth Prospects and Stable Financial Health Drive Buy Rating - TipRanks

Oct 16, 2025
pulisher
Oct 16, 2025

ABT Q3 Deep Dive: Q3 Results in Line with Expectations, Product Pipeline and Market Dynamics Shape Outlook - TradingView

Oct 16, 2025
pulisher
Oct 16, 2025

Abbott (ABT) Profit Margin Surge Challenges Bearish Narratives Despite Earnings Decline Forecast - simplywall.st

Oct 16, 2025
pulisher
Oct 15, 2025

Abbott Laboratories Reports Strong Q3 2025 Earnings - TipRanks

Oct 15, 2025
pulisher
Oct 15, 2025

Abbott (ABT) Margin Surge Reinforces Bullish Narratives Despite Earnings Decline Forecast - Yahoo Finance

Oct 15, 2025
pulisher
Oct 15, 2025

Abbott Laboratories’ Earnings Call Highlights Strong Growth - TipRanks

Oct 15, 2025
pulisher
Oct 15, 2025

Strong Performance and Future Potential: Buy Rating for Abbott Laboratories - TipRanks

Oct 15, 2025
pulisher
Oct 15, 2025

Why Abbott Laboratories (ABT) Stock Is Down Today - The Globe and Mail

Oct 15, 2025
pulisher
Oct 15, 2025

S&P Health Giant Skids On Mixed Third-Quarter News - Investor's Business Daily

Oct 15, 2025
pulisher
Oct 15, 2025

Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript - Fortune

Oct 15, 2025
pulisher
Oct 15, 2025

Abbott Laboratories (ABT) Q3 2025 Earnings Call Highlights: Strong Organic Growth and Medical ... - Yahoo Finance

Oct 15, 2025
pulisher
Oct 15, 2025

Abbott Laboratories (ABT) Stock Forecasts - Yahoo Finance

Oct 15, 2025
pulisher
Oct 15, 2025

Gold Gains Over 1%; Abbott Shares Fall After Q3 Results - Benzinga

Oct 15, 2025
pulisher
Oct 15, 2025

Abbott Laboratories (ABT) Q3 2025 Earnings Call Highlights: Stro - GuruFocus

Oct 15, 2025
pulisher
Oct 15, 2025

Abbott narrows outlook, Australian stocks react to US-China trade - Yahoo Finance

Oct 15, 2025

Abbott Laboratories Stock (ABT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
medical_devices BSX
$99.24
price up icon 1.49%
medical_devices SYK
$374.42
price up icon 1.40%
medical_devices MDT
$95.78
price up icon 0.78%
medical_devices EW
$74.64
price up icon 2.74%
$74.05
price up icon 0.91%
Cap:     |  Volume (24h):